Compare GVH & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GVH | ENVB |
|---|---|---|
| Founded | 2016 | 1994 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 3.0M |
| IPO Year | 2023 | N/A |
| Metric | GVH | ENVB |
|---|---|---|
| Price | $1.33 | $3.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $80.00 | ★ $120.00 |
| AVG Volume (30 Days) | ★ 1.2M | 161.8K |
| Earning Date | 02-15-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 11.95 | N/A |
| Revenue | ★ $21,878,867.00 | N/A |
| Revenue This Year | $141,706.20 | N/A |
| Revenue Next Year | $3.35 | N/A |
| P/E Ratio | $0.11 | ★ N/A |
| Revenue Growth | ★ 24.52 | N/A |
| 52 Week Low | $1.28 | $3.50 |
| 52 Week High | $364.00 | $75.60 |
| Indicator | GVH | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 30.20 | 43.97 |
| Support Level | $1.31 | $3.50 |
| Resistance Level | $1.58 | $4.29 |
| Average True Range (ATR) | 0.46 | 0.32 |
| MACD | -0.12 | -0.06 |
| Stochastic Oscillator | 1.37 | 31.52 |
Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.